The european exenatide study of long-term exenatide vs. glimepiride for type 2 diabetes: Rationale and patient characteristics

Diabetes, Obesity and Metabolism

Volumn 11, Issue 12, 2009, Pages 1131-1137

  Kazda, C ^a   Gallwitz, B ^b   Simo R ^c   Guzman J R ^d   Kraus, P ^a   Nicolay, C ^a   Rose, L ^e   Schernthaner, G ^f  

^a LILLY DEUTSCHLAND GMBH   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d Celaya Center for Specialist Medicine   (Mexico)

^e Center for Diabetes and Vascular Diseases   (Germany)

^f KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

Exenatide; Glimepiride; Patients characteristics; Type 2 diabetes

Indexed keywords

ANTILIPEMIC AGENT; EXENDIN 4; GLIMEPIRIDE; HEMOGLOBIN A1C; LIPID; METFORMIN;

ADD ON THERAPY; ADULT; ANAMNESIS; ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL STUDY; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DISEASE DURATION; DRUG DOSE TITRATION; DYSLIPIDEMIA; FEMALE; HUMAN; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EUROPE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PEPTIDES; SULFONYLUREA COMPOUNDS; VENOMS; YOUNG ADULT;

EID: 70450207537     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01091.x     Document Type: Article

References (33)

1. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003, 46:3-19.
2. Leroith D. Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities. Am J Med 2002, 113(Suppl. 6A):3S-11S.
3. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999, 104:787-794.
4. Overview of 6 years' therapy of type II diabetes: a progressive disease (UKPDS 16). Diabetes 1995, 44:1249-1258. UK Prospective Diabetes Study (UKPDS) Group
5. Nathan DM, Buse JB, Davidson MB. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia 2009, 52:17-30.
6. Consoli A, Gomis R, Halimi S. Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications. Diabetes Metab 2004, 30:509-516.
7. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000, 283:1695-1702.
8. Matthaei S, Haring HU. Behandlung des Diabetes mellitus Type 2. Diabetologie 2008, 3(Suppl. 2):S157-S161. German Diabetes Association
9. McIntosh A, Hutchinson A, Home PD. 2001, http://www.nice.org.uk, Clinical guidelines and evidence review for type 2 diabetes: management of blood glucose. Sheffield:ScHARR, University of Sheffield., Available from URL:
10. Kirpichnikov D. Metformin: an update. Ann Intern Med 2002, 137:25-33.
11. Cook MN, Girman CJ, Stein PP, Alexander CM, Holman RR. Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care 2005, 28:995-1000.
12. Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004, 26:2034-2044. Lispro Mixture-Glargine Study Group.
13. Goudswaard AN, Furlong NJ, Rutten GE, Stolk RP, Valk GD. Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. Cochrane Database Syst Rev 2005, 4:CD003418.
14. Nathan DM, Buse JB, Davidson MB. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia 2006, 49:1711-1721. Professional Practice Committee; American Diabetes Association; European Association for the Study of Diabetes.
15. Kahn SE, Zinman B, Lachin JM. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008, 31:845-851. Diabetes Outcome Progression Trial (ADOPT) Study Group.
16. Selvin E, Bolen S, Yeh HC. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 2008, 168:2070-2080.
17. Szayna M, Doyle ME, Betkey JA. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 2000, 141:1936-1941.
18. Young AA, Gedulin BR, Bhavsar S. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, Diabetic Fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 1999, 48:1026-1034.
19. Greig NH, Holloway HW, De Ore KA. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia 1999, 42:45-50.
20. Fehse F, Trautmann M, Holst JJ. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005, 90:5991-5997.
21. Parkes DG, Pittner R, Jodka C, Smith P, Young A. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 2001, 50:583-589.
22. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin treated patients with type 2 diabetes. Diabetes Care 2005, 28:1092-1100.
23. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2628-2635. Exenatide-113 Clinical Study Group.
24. Punthakee Z, Werstuck GH, Gerstein HC. Diabetes and cardiovascular disease: explaining the relationship. Rev Cardiovasc Med 2007, 8:145-153.
25. Phillips DI, Clark PM, Hales CN, Osmond C. Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet Med 1994, 11:286-292.
26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
27. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998, 21:2191-2192.
28. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
29. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005, 28:1245-1249. American Diabetes Association Workgroup on Hypoglycaemia
30. http://www.meddramsso.com/MSSOWeb/index.htm, MedDRA: Medial dictionary for Regulatory Activities. Available from URL:
31. Standards of medical care in diabetes. Diabetes Care 2006, 29(Suppl 1):S4-S38. American Diabetes Association
32. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854-865. UK Prospective Diabetes Study (UKPDS) Group
33. Stoffers DA. The development of beta-cell mass: recent progress and potential role of GLP-1. Horm Metab Res 2004, 36:811-821.